<unk>  is a 5HT1B/1D receptor agonist that is FDA approved for the treatment of migraine attacks in adults with a history of migraine with or without aura and migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more.   Common adverse reactions include dry mouth, paresthesia, dizziness, somnolence, headache, paresthesia, nausea and vomiting.
Almotriptan
Rizatriptan
Sumatriptan 
Eletriptan
Frovatriptan
Naratriptan
Zolmitriptan 
Beractant